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These results were then extrapolated using a Markov model that considered annual cycles and a 69-year period. The total timeframe considered for both models was 70 years.
Outcomes assessed in the review
The model parameters assessed were: the HBeAg seroconversion rates at year 1, 2, 3 and 4 after treatment with lamivudine and IFN-a, and the spontaneous seroconversion rate for patients not receiving treatment; and the rate of progression to cirrhosis after 12 months of treatment with lamivudine, IFN-a, and no treatment for patients who did not seroconvert.
Other epidemiological parameters were also assessed: the reactivation rate back to non-seroconverted CHB state during the first year after seroconversion; the annual progression rate to compensated cirrhosis for seroconverted patients and for patients with CHB; the annual rate of progression to decompensated cirrhosis; the annual progression rate to hepatocellular cancer for CHB patients who had not yet progressed to cirrhosis and for those with cirrhosis; the annual mortality rate for patients with compensated cirrhosis, with decompensated cirrhosis, and those with liver cancer.
Study designs and other criteria for inclusion in the review
Not reported. Among the studies included, there was one meta-analysis, several clinical trials, one randomised clinical trial, a prospective study, a retrospective cohort study, and some studies of epidemiological and demographic data.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
At least 29 studies appear to have been reviewed to obtain the effectiveness evidence.
Methods of combining primary studies
Not reported. Some effectiveness estimators (e.g. the HBeAg seroconversion rates at year 1) were calculated as a weighted average of the results obtained from several studies. in the review. They provided explanations for some of the differences found between the primary studies. No statistical tests of homogeneity appear to have been performed.
Results of the review
The HBeAg seroconversion rates at year 1 after treatment were 28.7% for patients treated with lamivudine, and 28.7% for patients treated with IFN-a.
For patients treated with lamivudine the rates for later years were 18.7% at 2 years after treatment, 39.6% at 3 years after treatment, and 22.9% at 4 years after treatment.
At years 1, 2, 3, and 4 the spontaneous seroconversion rate was 9% for patients not receiving treatment.
The spontaneous seroconversion rate was also 9% at years 2, 3 and 4 for patients treated with IFN-a.
The rates of progression to cirrhosis after 12 months for patients who did not seroconvert were 2% with lamivudine, 14% with IFN-a and 14% with no treatment.
Methods used to derive estimates of effectiveness
Estimates of effectiveness were also derived from a panel of experts, experts' opinions obtained through a questionnaire, and authors' assumptions.
Estimates of effectiveness and key assumptions
A panel of experts estimated the likely percentages of patients receiving each kind of treatment in each of the scenarios: in scenario A, 65% of patients would receive lamivudine, 12% would receive IFN-a, and 23% would not be treated; in scenario B, 20% of patients would be treated with IFN-a, and 80% would not receive treatment; in scenario C, none of the patients would receive treatment.
The authors formulated assumptions about the treatments:
the HBeAg seroconversion rate after year 4 was 9% for all patients in all scenarios; and treatment with lamivudine would have no benefit in the progression to cirrhosis after year 1.
Measure of benefits used in the economic analysis
The measures of health benefit used in the economic analysis were the number of life-years (LYs) and the number of quality-adjusted life-years (QALYs) gained under each of the scenarios during the 70-year period considered at analysis. Four members of the expert panel, using an Assessment of Quality of Life questionnaire, estimated quality of life utilities. These were combined with LYs in order to obtain the QALYs. The utility weights were not reported. 
Direct costs
The direct costs included in the study were those of the Australian health system. These were for drugs, consultations (general practitioner, specialist and hospital outpatient), tests and hospitalisation related to compensated cirrhosis, decompensated cirrhosis and hepatocellular cancer. The tests comprised liver function tests, DNA testing, full blood count, HBeAg and HBsAg tests, alpha-fetoprotein, ultrasound, thyroid function test, endoscopy and computed tomography scan of abdomen. The direct costs came from published studies and the findings from the hepatoogists' questionnaire. The published studies included data from the Pharmaceutical Benefits Schedule, the Medicare Benefits Schedule, and the National Hospital Cost Data Collection, among others. The findings of the questionnaire were ratified by an expert panel (both the hepatologists' questionnaire and the expert panel were the same as those used to derive the estimates of effectiveness). The authors also seem to have made some assumptions when estimating the costs. Therefore, the costs were estimated on the basis of actual data and a guess from experts.
The unit costs used in the economic analysis were reported. Some, but not all, of the resource quantities were reported separately from the costs. Discounting was performed at a rate of 5%. The price year was not reported. The study reported the average costs per patient and the incremental average costs per patient, according to each of the scenarios, for a timeframe of 70 years.
Statistical analysis of costs
No statistical analyses of the costs were performed.
Indirect Costs
No indirect costs were reported.
Currency
Australian dollars (Aus$).
Sensitivity analysis
Sensitivity analyses were performed to assess the robustness of the results. The parameters varied were those related to the assumptions about the proportion of patients receiving treatments, seroconversion rates, progression rates to cirrhosis, costs and probabilities of disease progression. The area of uncertainty investigated was, therefore, variability in the data. One-way analyses used appear to have been used. The authors did not report the ranges over which the parameters were varied.
Estimated benefits used in the economic analysis
From the short-term analysis, the percentages of patients who seroconverted during the first year of treatment were 24.2% in scenario A, 12.9% in scenario B and 9.0% in scenario C. The percentage of patients who progressed to cirrhosis were 5.1% (scenario A), 12.2% (scenario B) and 12.7% (scenario C), respectively.
Starting from the least effective scenario, the results of the long-term analysis showed that the incremental LYs gained was 0.6 under scenario B when compared with scenario C, and 5 for scenario A versus B.
The incremental QALYs gained was 0.6 under scenario B when compared with scenario C, and 4.1 for scenario A versus B.
These benefits were estimated for a timeframe of 70 years. The benefits were discounted at a rate of 5%.
It was not stated whether the expert panel considered the side effects of the treatments when estimating the utilities used to calculate the QALYs. patients under treatment in Australia. The authors stated that details of the panel process had been published. The authors' assumptions about health state transition probabilities appear to have been justified by reference to the medical literature. The authors reported that the assumptions were conservative against lamivudine. The estimates of effectiveness were investigated in sensitivity analyses, but the ranges over which the effectiveness parameters were varied were not reported.
There were several anomalies in the data used. First, the probability of seroconversion was the same for no treatment and IFN-a for patients eligible for both lamivudine and IFN-a. Second, there was a reduction in the probability of seroconversion from 0.287 to 0.09 from the first year to succeeding years.
Validity of estimate of measure of benefit
The estimation of benefits was modelled. The models used appear to have been appropriate. However, quality of life was derived from experts' opinions rather than from patients' opinions. Therefore, the utilities obtained may not be representative of patient preferences associated with health states and treatments. The health benefits obtained were discounted at a rate of 5%, which was appropriate. It was unclear whether the expert panel considered the side effects of the treatments when estimating the utilities used to calculate the number of QALYs gained.
Validity of estimate of costs
Most of the cost categories relevant to the perspective adopted appear to have been included in the economic analysis.
